Coronary Artery Disease ProgressionPREDICT-CVDNCT05800093
Proteomics and Genomics Combined With CT to Predict CVD
An observational study of Coronary Artery Disease Progression, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
Trial summary
This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis. Read more about this study
- Who is it for?
- Ages 50 to 75 years
- Conditions the study is for
- Coronary Artery Disease Progression
- How many people
- 312 participants
- Where
- 1 siteNetherlands
- Study dates
- 12 Jan 2023to 8 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Adult, Older adult
Study population: Adult patients between 50 and 75 years old with nonobstructive coronary artery disease
Who may be able to join
- Adult patients between 50 and 75 years old
- Subjects at intermediate to high risk for ASCVD
- Asymptomatic patients without cardiac chest pain
- Evidence of atherosclerosis on baseline CCTA
Who cannot join
- Renal insufficiency, defined as eGFR < 30 ml/min
- History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
- Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
- Change in lipid lowering therapy in the last 6 months
- Use of more than two antihypertensive agents
- No coronary atherosclerosis at baseline imaging
Show all 10Show fewer
- Active malignancy requiring treatment
- Atrial fibrillation
- Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.
- Conditions
- Coronary Artery Disease Progression
What is being measured
The primary outcome is the main question the study is designed to answer.
Coronary Artery Disease Progression
Measured: Through study completion, between 130-156 weeks
Secondary outcomes (9)
Presence of obstructive stenosis
Measured: Through study completion, between 130-156 weeks
Progression in number of significant (>50%) and severe (>70%) stenoses
Measured: Through study completion, between 130-156 weeks
Total plaque volume progression
Measured: Through study completion, between 130-156 weeks
Calcified plaque volume progression
Measured: Through study completion, between 130-156 weeks
Non-calcified plaque volume progression
Measured: Through study completion, between 130-156 weeks
Low-attenuation plaque volume progression
Measured: Through study completion, between 130-156 weeks
Change in Pericoronary Adipose Tissue CT-Attenuation
Measured: Through study completion, between 130-156 weeks
CAD-RADS progression (yes/no)
Measured: Through study completion, between 130-156 weeks
Progression in number of high-risk plaque characteristics (yes/no)
Measured: Through study completion, between 130-156 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2023
- Study start12 Jan 2023
- Primary completion8 Apr 2026
- Study completion8 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery Disease ProgressionStudies of the same condition, open and under way.
- More trials run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 312 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, E.S.stroes, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Investigators
- Erik SG Stroes, MD PhD, Principal investigator, Amsterdam UMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05800093
- Sponsor's protocol ID
- NL81913.018.22
- Acronym
- PREDICT-CVD
- Status last verified
- Oct 2026
- First submitted
- 13 Mar 2023
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Proteomics and Genomics Combined With CT to Predict CVD
- ClinicalTrials.gov ID
- NCT05800093
- Acronym / sponsor ID
- PREDICT-CVD / NL81913.018.22
- Conditions
- Coronary Artery Disease Progression
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 312 participants (actual)
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)University, hospital or other
- Study start
- 12 Jan 2023 (actual)
- Primary completion
- 8 Apr 2026 (actual)
- Study completion
- 8 Apr 2026 (actual)
- First posted
- 5 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patients between 50 and 75 years old with nonobstructive coronary artery disease
Key inclusion criteria (4 listed)
- Adult patients between 50 and 75 years old
- Subjects at intermediate to high risk for ASCVD
- Asymptomatic patients without cardiac chest pain
- Evidence of atherosclerosis on baseline CCTA
Key exclusion criteria (10 listed)
- Renal insufficiency, defined as eGFR < 30 ml/min
- History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
- Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
- Change in lipid lowering therapy in the last 6 months
- Use of more than two antihypertensive agents
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Coronary Artery Disease Progression
Time frame: Through study completion, between 130-156 weeks
9 secondary outcomes
Presence of obstructive stenosis
Time frame: Through study completion, between 130-156 weeks
Progression in number of significant (>50%) and severe (>70%) stenoses
Time frame: Through study completion, between 130-156 weeks
Total plaque volume progression
Time frame: Through study completion, between 130-156 weeks
Calcified plaque volume progression
Time frame: Through study completion, between 130-156 weeks
Non-calcified plaque volume progression
Time frame: Through study completion, between 130-156 weeks
Low-attenuation plaque volume progression
Time frame: Through study completion, between 130-156 weeks
Change in Pericoronary Adipose Tissue CT-Attenuation
Time frame: Through study completion, between 130-156 weeks
CAD-RADS progression (yes/no)
Time frame: Through study completion, between 130-156 weeks
Progression in number of high-risk plaque characteristics (yes/no)
Time frame: Through study completion, between 130-156 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
Related trials for Coronary Artery Disease Progression
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
Not yet recruitingObservational study
AI-Based CT Analysis of Coronary Plaque Evolution
Coronary Artery Disease
RecruitingPhase 4
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
Obesity & Overweight, Coronary Heart Disease
Active, not recruitingPhase 3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Active, not recruitingObservational study
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
Melanoma, Atherosclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Erik SG Stroes, MD PhD principal investigator
Amsterdam UMC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease Progression, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Coronary Artery Disease Progression (time frame: Through study completion, between 130-156 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.